THURSDAY, MAY 23, 2024
TIME: 11:30 – 12:15 PM ET / 5:30 - 6:15 PM CET
The therapeutic landscape for treating relapsed/refractory chronic lymphocytic leukemia (R/R CLL) is rapidly evolving, with numerous trials and approvals leading to the availability of multiple treatment options. Though this range of therapies enables the individualization of treatment for patients, it also creates a need to establish optimal treatment sequencing.
In this live virtual event, experts will review the current treatment guidelines for R/R CLL and the latest data and approvals. They will discuss the best practices for treating patients, which factors to consider when selecting a treatment and how to incorporate the latest approvals to ensure patients receive the best available therapy. They will also look ahead to the upcoming European Hematology Association (EHA) 2024 congress, and comment on the most promising abstracts to be presented at the meeting.
Join this essential webinar on targeted therapies for R/R CLL developed by Medscape Global Oncology and the Lymphoma Coalition.
FACULTY
Chaitra Ujjani, MD
SPEAKER
Clinical Director of Lymphoma, Fred Hutchinson Cancer Center; Clinical Professor of Medicine, University of Washington, Washington, United States
Othman Al-Sawaf, MD
SPEAKER
University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
